Region becomes country’s first to speed up bowel cancer screening using technology as part of Levelling Up Smart City Region programme.

ICU nurse and creator of the Right to Rehab Campaign, Kate Tantam, shares her perspective on the importance of universal access to rehabilitation in the NHS.

Despite major gains in diagnosis and treatment, England continues to experience high disparities in cancer outcomes, with social and financial deprivation major drivers.

New report finds that people are more likely to leave work due to a heart condition than any other health issue, and warns that faltering efforts at prevention have cost thousands of lives.

Study proves efficacy of HPV vaccination at preventing cervical cancer, as UK Health Security Agency statistics show that uptake has still not returned to pre-pandemic levels.

The report from Demos and Breast Cancer Now estimates the economic and wider societal costs of breast cancer and urges UK governments to enact measures to reduce the burden of the disease.

Negotiations have concluded around the implementation of the Pharmacy First scheme, which is now set to launch in full on 31st January 2024.

By Fran Ward, Project Manager, NHS Arden & GEM CSU and Dr Paulina Ramirez, Academic, Birmingham Business School.

Service uses population health data to identify those most at risk of having surgery postponed

By Sara Hazzard, Assistant Director Strategic Communications at The Chartered Society of Physiotherapy (CSP) and Co-Chair Community Rehabilitation Alliance

Suicide rate among Gypsy, Roma and Traveller community is up to seven times higher than for all other communities in England, with poor service provision identified as major factor.

It is estimated that more than a million people in the UK have lower limb ulceration. With their 160 years' experience in developing wound care solutions, L&R hypothesised that a self-care delivery model could both improve outcomes and ease the burden on the healthcare system.

Report finds total number of retired benefits recipients likely to rise by 60 per cent in next decade, with costs expected to rise to £10.5bn.

New report from Sanofi shines a light on the hidden financial burden faced by sufferers of severe atopic eczema.